NCT04472910View on ClinicalTrials.gov

GATA6 Expression as a Predictor of Response to Peri-Operative Chemotherapy in Resectable Pancreatic Adenocarcinoma

NAActive, not recruitingINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

August 21, 2020

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Resectable Pancreatic Cancer
Interventions
DRUG

Modified Folforinox (mFFX)

Neo-adjuvant mFFX for up to 6 cycles, chemo-Adjuvant FFX q 2 weekly or other approach as per investigator to complete up to 6 months chemotherapy

Trial Locations (8)

Unknown

BC Cancer Agency Vancouver, Vancouver

Kingston Health Sciences Centre, Kingston

London Health Sciences Centre, London

Ottawa Hospital, Ottawa

Sunnybrook Hospital/Odette Cancer Centre, Toronto

Unity Health (St. Joseph's and St. Michael's), Toronto

Jewish General Hospital, Montreal

M5G 2N9

Princess Margaret Cancer Centre, Toronto

All Listed Sponsors
collaborator

Pancreatic Cancer Canada

OTHER

lead

University Health Network, Toronto

OTHER